EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Modeling Drug and Radiation Resistance with Patient-Derived Organoids: Recent Progress, Unmet Needs, and Future Directions for Lung Cancer

Dahye Lee iD, Yoonjoo Kim iD, Da Hyun Kang iD, Chaeuk Chung iD

Cells · 15.12.2025 · 14 (24) · 1994

DOI: 10.3390/cells14241994 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cells, online erschienen am 15.12.2025. Verfasst von Dahye Lee und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pulmonology and Critical Care Medicine, Department of Internal Medicine, College of Medicine, Chungnam National University, Daejeon 34134…. Hauptthemen laut MEDLINE: Organoids, Lung Neoplasms, Drug Resistance, Neoplasm, Radiation Tolerance. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 102 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea, grant of the Korea Health Technology R&D Project, grant of the Korea Health Technology R&D Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Chemotherapy, targeted therapy and radiotherapy are the cornerstones of cancer treatment. However, therapeutic resistance—not only to these classic modalities but also to novel therapeutics like immune checkpoint inhibitors (ICIs) and antibody-drug conjugates—remains a major hurdle. Resistance significantly limits efficacy and increases recurrence rates. A deep understanding of the molecular mechanisms driving this resistance is critical for developing personalized therapeutic strategies and improving patient outcomes. Recent Advances: Patient-derived cancer organoids have emerged as a powerful preclinical platform that faithfully recapitulates the genetic, phenotypic, and histological characteristics of original tumors. Consequently, PDOs are being widely utilized to evaluate drug responses, investigate resistance mechanisms, and discover novel therapeutic targets for a range of therapies.

Limitations

While organoid models have been instrumental in studying resistance, significant limitations persist. First, standard organoid-only models lack key tumor microenvironment components, such as immune cells, limiting immunotherapy research. Second, there is a significant lack of research on acquired resistance, particularly in lung cancer. This gap is largely driven by the clinical infeasibility of rebiopsy in patients with progressive diseases. Third, the absence of standardized protocols for generating and validating resistance models hinders reproducibility and complicates clinical translation.

Conclusions

This review summarizes recent advances in using organoid models to study resistance to chemotherapy, radiotherapy, and novel therapeutics (ICIs and ADCs). We emphasize the critical need for standardization in resistance organoid research. We also propose future directions to overcome existing challenges, including the integration of co-culture systems (to include the TME) and advanced technologies (e.g., scRNA-seq, Spatial Transcriptomics). Our specific focus is on advancing lung cancer resistance modeling to enable functional precision medicine.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OrganoidsLung NeoplasmsDrug Resistance, NeoplasmRadiation ToleranceModels, BiologicalHumansTumor MicroenvironmentPrecision Medicine

Stichwörter der Autor:innen

acquired resistanceantibody-drug conjugateschemotherapy resistanceimmune checkpoint inhibitorslung cancerpatient-derived organoidradiotherapy resistancesingle cell RNA sequencingspatial transcriptomicstumor microenvironment

Autor:innen und Institutionen

  • Division of Pulmonology and Critical Care Medicine, Department of Internal Medicine, College of Medicine, Chungnam National University, Daejeon 34134, Republic of Korea.

ORCID-Profile: Dahye Lee, Yoonjoo Kim, Da Hyun Kang, Chaeuk Chung

Förderung

  • National Research Foundation of Korea
  • grant of the Korea Health Technology R&D Project
  • grant of the Korea Health Technology R&D Project

Zitieren

APA

Lee, D., Kim, Y., Kang, D. H., & Chung, C. (2025). Modeling Drug and Radiation Resistance with Patient-Derived Organoids: Recent Progress, Unmet Needs, and Future Directions for Lung Cancer. Cells, 14(24), 1994. https://doi.org/10.3390/cells14241994

Vancouver

Lee D, Kim Y, Kang DH, Chung C. Modeling Drug and Radiation Resistance with Patient-Derived Organoids: Recent Progress, Unmet Needs, and Future Directions for Lung Cancer. Cells. 2025;14(24):1994. doi:10.3390/cells14241994

BibTeX
@article{Lee2025,
  author = {Lee, Dahye and Kim, Yoonjoo and Kang, Da Hyun and Chung, Chaeuk},
  title = {Modeling Drug and Radiation Resistance with Patient-Derived Organoids: Recent Progress, Unmet Needs, and Future Directions for Lung Cancer},
  journal = {Cells},
  year = {2025},
  volume = {14},
  number = {24},
  pages = {1994},
  doi = {10.3390/cells14241994}
}
Kostenlos starten →